Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046368 | 1.00 | LPAR3 (0.56) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL10138608 | 0.88 | LPAR3 (0.46) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL8904061 | 0.87 | LPAR3 (0.48) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL20580710 | 0.87 | LPAR3 (0.48) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL20193278 | 0.87 | LPAR3 (0.48) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL10561282 | 0.86 | CYP3A4 (0.69) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL887888 | 0.86 | CYP3A4 (0.69) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL30298895 | 0.86 | CYP3A4 (0.69) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL872514 | 0.86 | CYP3A4 (0.69) | LPAR3LPAR1LPAR2CYP3A4TSHR | |
| SCHEMBL18139463 | 0.86 | CYP3A4 (0.69) | LPAR3LPAR1LPAR2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310912-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2013-11-21 | — | — | US | disclosed |
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | LPAR3 4317/4885LPAR1 4255/4885LPAR2 4339/4885 |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | LPAR3 4317/4885LPAR1 4255/4885LPAR2 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.